The U.S. FDA has approved nivolumab (Opdivo) in combination with AVD chemotherapy for patients aged 12 and older with newly diagnosed advanced classical Hodgkin lymphoma. This approval expands access to a modern immunotherapy-based treatment for both adults and adolescents.
Results from the SWOG 1826 trial showed the combination reduced the risk of disease progression or death by 58% compared to the previous standard regimen. Outcomes in adolescents were especially strong, with a three-year progression-free survival rate of 93%. The need for radiation therapy dropped sharply, with only 1.3% of patients requiring it.
The regimen also showed lower rates of nerve damage but requires monitoring for thyroid-related side effects. It simplifies care with fewer clinic visits and less need for supportive medications. While the results are promising, experts note that long-term effects—especially in younger patients—still need further study.